Informed consent signed by the participant prior to conducting study-specific procedures  2. ≥18 years of age 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (see Appendix 5) 4. Histological or cytological diagnosis of: a. Part A: advanced B-cell lymphomas or solid tumors, of the following subtypes: i. B-cell Lymphomas 1. Mantle cell lymphoma (MCL) 2. Diffuse large B-cell lymphoma (DLBCL) (including Richter's transformation) 3. Follicular lymphoma  4. Small lymphocytic lymphoma (SLL) ii. Solid Tumors 1. Pancreatic cancer 2. Non-squamous non-small cell lung cancer (NSCLC)  3. Malignant mesothelioma 4. Epithelial ovarian cancer. Participants with fallopian tube and/or peritoneal malignancies are also eligible. 5. Triple-negative breast cancer.  6. Liposarcoma iii. Other, unlisted histologies, if approved by the Sponsor Medical Monitor b. Part B Cohorts B1, B2, and B3: Histological or cytological diagnosis of the cohort-specific disease indication. Indications may include those listed in Inclusion Criterion 4a 5. Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants must be relapsed or refractory to, have developed an intolerance to, or not be candidates for available therapies with established benefit. Participants with B-cell malignancies should have received at least two lines of therapy, including available therapies with established benefit. Participants with SLL should have received at least three prior lines of therapy.  6. Participants must have measurable disease as per the relevant response assessment framework: Lugano Classification for lymphoma (except SLL) (Cheson et al. 2014), per iwCLL criteria for SLL (Hallek et al. 2008), and per RECIST v.1.1 for solid tumors (Eisenhauer et al. 2009) (see Appendix 3).  7. Participants who are considered women of childbearing potential (WOCBP; see Appendix 1 for definitions) must: Confidential  Page 52 of 116 Immunome, Inc. IM-1021 Protocol IM-1021-101  a. Have a negative pregnancy test and be willing to practice at least one of the highly effective methods of birth control described in Appendix A1-2.1 from the start of the screening period until 9 months after the last dose of study treatment.  b. Be willing to refrain from donating oocytes for the duration of the study and for 9 months after the last dose of study treatment. 8. Participants who are assigned male at birth must: a. Have undergone bilateral vasectomy or bilateral orchiectomy OR be willing to practice at least one of the highly effective methods of birth control described in Appendix A1-2.1 from the start of the screening period until 9 months after the last dose of study treatment if partner is a WOCBP. b. Be willing to use a male condom with all partners during treatment and for 3 months after the last dose of study treatment to prevent exposure to bodily fluids. c. Be willing to refrain from donating sperm for the duration of the study and for 6 months after the last dose of study treatment. 9. Resolution of prior therapy-related AEs to grade ≤ 1 per CTCAE v5.0 (excluding alopecia and grade ≤ 2 peripheral neuropathy). Ongoing electrolyte and hormonal supplementation may be used to treat these AEs provided the participant is stable on these supplements. 10. Minimum of 5 half-lives or 2 weeks since the last dose of systemic cancer therapy, whichever is shorter.  11. Participants must have adequate organ function as indicated by the following laboratory values. Growth factor support is not permitted within 2 weeks before the start of study treatment to meet the below hematology values.  

Participants are excluded from the study if any of the following criteria apply: 1. Previously treated with an ADC with a topoisomerase-1 inhibitor payload, except: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload. 2. Previously received a ROR1-targeted therapy (eg, ADC, cell therapy, or monoclonal antibody). 3. History of an anaphylactic reaction to irinotecan or ≥ grade 3 GI toxicity to prior irinotecan. 4. Life expectancy < 12 weeks. 5. Prior solid organ transplant. 6. Participants with symptomatic ascites or pleural effusion. Participants who are clinically stable for at least 2 weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis or catheter) are eligible. 7. Participant has a known active central nervous system (CNS) primary tumor or metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to study entry, have no radiological evidence of new or enlarging brain metastases, and are off steroids or on a stable dose up to an equivalent of prednisone 10 mg/day for at least 15 days prior to first dose of study medication. Participants who have symptoms consistent with CNS metastasis must have a negative contrast-enhanced magnetic resonance imaging (MRI) or other clinically appropriate imaging study if the participant is not able to undergo contrast-enhanced MRI and approved by the Sponsor Medical Monitor during the screening period. 8. Participant has a known history of malignant primary brain tumor, or another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of that disease for at least 2 years. Exception: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers. 9. Participant has a clinically significant uncontrolled heart disease and/or cardiac repolarization abnormality, including but not limited to: a. QTcF > 470 msec regardless of sex assigned at birth. b. Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome. c. Myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 3 months prior to start of study therapy. d. Unstable angina  e. Uncontrolled grade ≥ 3 hypertension (diastolic blood pressure ≥ 100 mmHg or systolic blood pressure ≥ 160 mmHg) despite antihypertensive therapy. 10. Recent or ongoing serious infection including the following: a. Any uncontrolled grade 3 or higher (per CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of IM-1021. Routine antimicrobial prophylaxis is allowed. b. Uncontrolled infection with HIV. Participants on stable highly active antiretroviral therapy (HAART) with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required. c. Known to be positive for hepatitis B surface antigen, or any other positive test for hepatitis B indicating acute or chronic infection. Participants who are or have received anti-HBV therapy and have undetectable HBV DNA for at least 6 months prior to study entry are eligible. Serological testing for hepatitis B at screening is not required. d. Known active hepatitis C as determined by positive serology and confirmed by PCR. Participants on or having received anti-retroviral therapy are eligible provided they are virus-free by PCR for at least 6 months prior to study entry. Serological testing for hepatitis C at screening is not required. e. Known active or untreated latent tuberculosis (testing at screening is not required). 11. Participant has received an investigational product or been treated with an investigational device within 28 days (or 5 half-lives whichever is longer) prior to first administration of study medication. 12. Concurrent therapy with anti-cancer or anti-neoplastic drugs, with the exception of ongoing adjuvant hormonal therapy, which is allowed provided the participant has undergone potentially curative therapy with no evidence of disease for at least 2 years. 13. History or clinical evidence of any surgical or medical condition that the Investigator judges as likely to interfere with the results of the study or pose an additional risk in participating, eg, rapidly progressive or uncontrolled disease involving a major organ system - vascular, cardiac, pulmonary, gastrointestinal, gynecologic, hematologic, neurologic, neoplastic, renal, endocrine, autoimmune or an immunodeficiency, or clinically significant active psychiatric or abuse disorders.